恩度联合第三代含铂(NP方案)治疗晚期非小细胞肺癌临床研究

Combined with the third generation platinum(NP) for the treatment of advanced non small cell lung cancer

目的探讨恩度联合第三代含铂(NP方案)治疗晚期非小细胞肺癌临床疗效。方法选取2008年3月至2012年1月收治符合入选标准晚期非小细胞肺癌98例,分为联合治疗组60例,NP方案组38例,观察临床近期疗效。结果联合治疗组有效率40.0%、临床受益率80.0%,显著优于NP方案组有效率31.5%、临床受益率68.4%,经统计学分析,有显著差异性(P<0.05)。结论血管内皮抑素(endostatin)是一种内源性糖蛋白,最早在鼠成血管细胞瘤株培养液中进行分离提纯得到的,具有抗血管生成作用;新型重组人血管内皮抑制素(恩度)是我国自主开发,可靶向人类基因组血管生成调节基因超过12%,对血管内皮细胞的迁移、附着、生长抑制,抑制新生血管生成,对血管内皮细胞凋亡有着直接影响,对肿瘤新生血管生成有着显著抑制作用,发挥抑制肿瘤生长作用。在晚期非小细胞非癌治疗中采取恩度(血管内皮抑制素)联合第三代含铂(NP方案)可以显著提高有效率及临床受益率。

Objective To explore the clinical curatire effect of the combined with the third generation platinum （NP） for the treatment of advanced non small cell lung cancer. Methods From 2008 march to 2012 year in January admits to be eligible for advanced non small cell lung cancer 98 cases, divided into the treat- ment group 60 cases, NP group 38 cases, observation of clinical efficacy. Results The combined treatment group was 40%, the clinical benefit rate of 80%, significantly better than the NP group was 31.5%, the clini- cal benefit rate 68.4%, there were significant differences （ P 〈 0. 05 ）. Conclusion Endostatin （endostatin） is an endogenous glycoproteins, the earliest in the rat vascular cell culture medium for separating and purifying to obtain, with antiangiogenic effect. Model of recombinant human endostatin （TU） is China＇s independent de- velopment, may be targeting the human genome angiogenesis-modulating genes over 12%, on vascular endothe- lial cell migration, attachment, growth inhibition, inhibition of angiogenesis, on apoptosis of vascular endotheli- al cells have a direct impact on tumor angiogenesis, have significant inhibition of tumor growth inhibition effect, play. In advanced non small cell cancer treated with Endostar （taken in endostatin） combined with the third generation platinum （NP） can improve the efficiency and clinical benefit rate.